top of page

Best selling cancer drugs of 2024 | Top cancer drugs by revenues in 2024 | iPharmaCenter






$6.9 billion



$2.7 billion



$2.1 billion



$1.7 billion



$1.6 billion



$1.6 billion



$1.1 billion



$1.0 billion



$1.0 billion



$1.0 billion

Best selling cancer drugs of 2024

1. Keytruda (Pembrolizumab)

Company: Merck & Co.

Mechanism of Action: Keytruda is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1). By blocking PD-1, it enhances the immune system’s ability to recognize and attack cancer cells.

Indications: Keytruda is approved for various cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and more.

The Merck Access Program for Keytruda provides valuable resources and support for healthcare professionals and their patients.

  • Coverage Assistance: The program helps determine coverage for patients by offering information about the Merck Co-pay Assistance Program and the Merck Patient Assistance Program. It can assist with benefit investigations, billing and coding, co-pay assistance for eligible patients, prior authorizations, appeals processes, and referrals to the Merck Patient Assistance Program for eligibility determination1.

  • Co-pay Assistance: Privately insured patients who need help affording the out-of-pocket costs for KEYTRUDA can benefit from the Merck Co-pay Assistance Program. Eligible patients pay only the first $25 of their co-pay per infusion, with a maximum benefit of $25,000 per patient during each eligibility period2.

  • Reimbursement and Insurance Coverage: The Merck Access Program provides reimbursement and insurance coverage-related information throughout the patient’s treatment process

2. Darzalex (Daratumumab)

  • Company: Johnson & Johnson

  • Mechanism of Action: Darzalex is a monoclonal antibody that targets CD38 on the surface of myeloma cells. It induces cell death and enhances the immune system’s response against cancer.

  • Indications: Darzalex is primarily used for multiple myeloma.

  • Successful Factors: Its efficacy, especially in relapsed/refractory myeloma, and ongoing clinical trials contribute to its popularity.

3. Opdivo (Nivolumab)

  • Company: Bristol Myers Squibb

  • Mechanism of Action: Opdivo is another PD-1 inhibitor, similar to Keytruda. It unleashes the immune system to fight cancer cells.

  • Indications: Opdivo is approved for various cancers, including melanoma, lung cancer, renal cell carcinoma, and more.

  • Successful Factors: Opdivo’s broad indications, durable responses, and combination therapies make it a top choice1.

4. Revlimid (Lenalidomide)

  • Company: Bristol Myers Squibb

  • Mechanism of Action: Revlimid modulates the immune system and has anti-angiogenic properties. It is used primarily for multiple myeloma and myelodysplastic syndromes.

  • Indications: Multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes.

  • Successful Factors: Revlimid’s efficacy, oral administration, and ongoing research contribute to its sales1.

5. Imbruvica (Ibrutinib)

  • Company: Johnson & Johnson (in partnership with AbbVie)

  • Mechanism of Action: Imbruvica inhibits Bruton’s tyrosine kinase (BTK), disrupting B-cell signaling pathways. It is effective against B-cell malignancies.

  • Indications: Chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia.

  • Successful Factors: Imbruvica’s targeted therapy and clinical evidence drive its sales.

6. Tagrisso (Osimertinib)

  • Company: AstraZeneca

  • Mechanism of Action: Tagrisso is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It targets EGFR mutations in non-small cell lung cancer.

  • Indications: Non-small cell lung cancer with EGFR T790M mutations.

  • Successful Factors: Tagrisso’s specificity for EGFR mutations and improved survival rates contribute to its popularity.

7. Imfinzi (Durvalumab)

  • Company: AstraZeneca

  • Mechanism of Action: Imfinzi is another PD-1/PD-L1 inhibitor. It enhances the immune response against cancer cells.

  • Indications: Non-small cell lung cancer, bladder cancer, and other solid tumors.

  • Successful Factors: Imfinzi’s role in immunotherapy and ongoing clinical trials drive its sales.

8. Ibrance (Palbociclib)

  • Company: Pfizer

  • Mechanism of Action: Ibrance inhibits cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6. It is used in breast cancer.

  • Indications: Metastatic breast cancer.

  • Successful Factors: Ibrance’s targeted approach and combination therapies contribute to its market share.

9. Verzenios (Abemaciclib)

  • Company: Eli Lilly

  • Mechanism of Action: Verzenios also inhibits CDK4 and CDK6. It is used in breast cancer.

  • Indications: Breast cancer

10. Tecentriq (Atezolizumab)

  • Company: Roche/Genentech

  • Mechanism of Action: Tecentriq is a PD-L1 inhibitor, similar to Keytruda and Opdivo. It blocks the interaction between PD-L1 and PD-1, allowing the immune system to attack cancer cells.

  • Indications: Tecentriq is used in various cancers, including bladder cancer, non-small cell lung cancer, and triple-negative breast cancer.

  • Successful Factors: Tecentriq’s efficacy in specific cancer types and ongoing research contribute to its sales.


Recent Posts

See All


bottom of page